

Too many choices : how information departments evaluate and choose new information tools

ICIC 21st Meeting

18-21 October 2009

Sitges, Spain

Fabienne BERTHET, PhD,
Scientific Information Services Director

WHERE WE HAVE COME FROM



A GROUP ORIGINATING FROM A FAMILY BUSINESS


AN HISTORICAL PRESENCE IN PRIMARY CARE

AN EARLY COMMITMENT TO RESEARCH





AN INNOVATION DRIVEN INTERNATIONAL SPECIALTY PHARMACEUTICAL GROUP

- Direct commercial presence in over **30** countries
- Over **20** products marketed in more than **100** countries
- **4** R&D centres
- **9** Manufacturing sites, representing more than 1,100 employees
- **More than 4,200** employees worldwide including 800 in R&D



A STRATEGIC FOCUS ON TARGETED DISEASE AREAS


- 4 targeted disease areas (oncology, endocrinology, neurology and haematology)
- Double digit growth rate






A DIFFERENTIATING RESEARCH AND DEVELOPMENT CAPABILITY

- Focused on hormone-dependent diseases, peptide and protein engineering and innovative delivery systems
- About 19% of sales allocated to R&D in 2008
- 4 centres in Boston, Paris, London and Barcelona
- More than 800 people dedicated to R&D activities
- Over 20 ongoing R&D programmes



IPSEN IN THE WORLD



OUR SCIENTIFIC INFORMATION SERVICES



A REMOTE TEAM


DEDICATED TO SUPPORT ALL IPSEN GROUP FUNCTIONS

OUR MISSION

- Our mission is to help Ipsen entities become more competitive by a better use of information coming from their external environment. Getting the right information at the right time is the best means of limiting risks and making the best decision for the company. This applies particularly to information available on the Internet and other published information in general, including journals and commercial databases.

- **3 functions within the same department :**
 - Library management
 - Scientific and technological watch to support R&D
 - Medical watch to support Operations

TOOL JUNGLE



A TOOL FOR WHAT? FOR WHOM?

MANAGE INFORMATION AND KNOWLEDGE RATHER
THAN DATA

INFORMATION SERVICES AND KNOWLEDGE REPOSITORY



EACH INFORMATION STEP REQUIRES TOOLS

Searching and watch

Traditional vendors (Dialog) / Google
SDI / RSS feeds and Google reader

Gathering

“Dedup” command / Federated search

Analysis

Synthesis and bibliographic statistics /
Text mining, semantic and visualization


Dissemination

Mails, portals / blogs and
Knowledge sharing communities

END USER NEEDS VERSUS PROFESSIONAL APPROACH

- **End user expectations are similar to their personal behaviors in daily life**
 - Quick, simple, user friendly, intuitive - Google mania
 - No consideration for comprehensive searches (some references are enough)
 - Why care about Intellectual Property if we can technically download and store data?
 - Much more opportunities to use web2.0 tools outside the company!
 - No fun in company applications
- **How be attractive as an information professional? What is really our added value?**
- **As many similar files and databases format co-exist, sharing similar goals, data format standardization problem is a well-known aspect of the “too many tools for too small missions” crisis.**

TOOL JUNGLE




A TOOL FOR WHAT? FOR WHOM?

**MANAGE INFORMATION AND KNOWLEDGE RATHER
THAN DATA**

WHAT KIND OF KNOWLEDGE REPOSITORY?

Manage information and knowledge rather than data

R&D Drug pipeline 2.0



Manage information and knowledge rather than data

Literature watch 1.0



DECAPEPTYL

ALERT BULLETIN
Week 39: 6th October 2009*

Sources:

MEDLINE, EMBASE, BIOSIS

Time coverage:

This update covers literature that has been published onto these databases since the last update (29th September 2009) *

Contents:

GnRH agonists , GnRH antagonists, and antiandrogens

Terms of Search:



PART I: GnRH agonists and antagonists.....	4
Part I A: Prostate cancer.....	4
Part I B: andrology.....	24
Part I C: gynaecological uses.....	24
Part I D: pediatric uses.....	45
Part I E: other uses.....	47
Part I F: tolerance (citations either duplicated from other topics or not).....	49
Part I G: pharmacology.....	57
Part I H: chemistry.....	89
PART II: Antiandrogens.....	89
Part II A: Clinical uses.....	89
Part II B: pharmacology.....	90

NOTE:

For all congress abstracts:
Open Ipsen Planet Intranet section and log in with your Internet

Manage information and knowledge rather than data

Literature watch 2.0

ACROMEGALY/PEGVISOMANT

Successful use of weekly pegvisomant administration in patients with acromegaly

Author/s Higham CE, Thomas JD, Bidlingmaier M, Drake WM, Trainer PJ.

Source Eur J Endocrinol. 2009 Jul;161(1):21-5

FullText <http://www.eje-online.org/cgi/reprint/161/1/21?>

IPSEN COMMENTS

Very small study.

Currently, pegvisomant weekly administration has been investigated mainly in co-administration studies (with somatostatin analogues).

Those results are supportive of the weekly mode of administration even when no somatostatin analogue is associated. This trend is observed in practice even if it is not pegvisomant labelling

Main Investigated drugs Pegvisomant

Study type Open-label prospective study

Indication Acromegaly


Number of patients: 7

What was investigated

The efficacy of weekly dosing of Pegvisomant

How it was investigated

A two center, open-label prospective study in patients with acromegaly converted from a stable daily dose of pegV (median dose 15 mg daily (range 10-20 mg od), IGF1 normal for 3 months prior to inclusion) to twice-weekly (week 0-16) followed by once-weekly (week 16-32) administration



The most important information


Serum IGF-I and pegvisomant levels were measured one day post-dose and prior to the next dose in five patients during the weekly administration of pegvisomant. There was no significant difference between serum IGF-I (post-dose 129 ± 6.9 vs pre-dose 137 ± 22 ng/ml) or pegvisomant concentrations (post-dose $17,200 \pm 11,500$ vs pre-dose $14,900 \pm 6600$ ng/ml) although these decreased in 4 out of 5 patients over the week. Serum IGF-I values remained within reference range throughout the week following injection (Figure 3).

Safety and QOL parameters remained stable.

Author conclusions

To conclude, we have demonstrated that conversion to sole pegvisomant administration on a weekly basis can be achieved safely, with no loss of efficacy or increase in dose requirements and

TOOL JUNGLE



A TOOL FOR WHAT? FOR WHOM?

MANAGE INFORMATION AND KNOWLEDGE RATHER
THAN DATA

WHAT KIND OF KNOWLEDGE REPOSITORY?

Full text link to the scanned document if copyright compliant

[Other bases](#) [Easy search](#) [Advanced search](#) [Help](#)

Author(s): [Ambrosio MR*](#), [Franceschetti P*](#), [Bondanelli M*](#), [Doga M*](#), [Maffei P*](#), [Baldelli R*](#), [Tamburrano G*](#), [Sicolo N*](#), [Giustina A*](#), [deglì Uberti EC](#)

Institution: Department of Biomedical Sciences and Advanced Therapies, Section of Endocrinology, University of Ferrara, Italy.

Title: Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.

Language: Eng

Source: [Metabolism](#) 2002 Mar; 51(3): 387-93



Year: 2002

Abstract: Recently, a new slow-release (SR) formulation of lanreotide (LAN) comprising 60 mg of the drug incorporated in microspheres of biodegradable polymers (SR-LAN 60) has become available. The aim of our study was to assess the effectiveness of SR-LAN 60, administered every 21 to 28 days, as well as its tolerability in the long-term treatment of acromegalic patients treated with SR-LAN 30. Twenty patients with acromegaly (10 males and 10 females) were enrolled in this open study. Thirteen patients had undergone surgery, but with incomplete resection of the pituitary tumor. All patients, treated with intramuscular (IM) SR-LAN 30 injections every 10 days for 12 to 24 months, started SR-LAN 60 (Ipsen-Beaufour, Milan, Italy) administration 10 days after the last injection of SR-LAN 30. Growth hormone (GH) levels were determined on the day of the first injection of SR-LAN 60, and 10, 20, and 30 days after. According to the GH levels reached on day 30, patients received SR-LAN60 every 28 days if GH levels were below 2.5 microg/L (group A) and every 21 days if GH levels were above 2.5 microg/L (group B). In group A, after the 8th month, SR-LAN 60 treatment resulted in well-controlled GH levels in 9 of 10 patients in comparison to SR-LAN 30 treatment every 10 days (6 of 10 patients). Normal age-adjusted insulin-like growth factor-I (IGF-I) levels were achieved in 4 of 10 patients, as in treatment with SR-LAN 30. In group B, SR-LAN 60 treatment resulted in well-controlled GH levels in 4 of 10 patients, as in treatment with SR-LAN 30 every 10 days. Normal age-adjusted IGF-I levels were achieved in 3 of 10 patients after SR-LAN 60 in comparison to SR-LAN 30 treatment every 10 days (1 of 10 patients). During SR-LAN 60 therapy, an improvement was also observed in signs and symptoms of active acromegaly and no relevant side effects were detected. In conclusion, this study shows that SR-LAN 60 treatment is able to induce a good control of circulating GH and IGF-I levels in most acromegalic patients. The first injections of SR-LAN 60 are very helpful in predicting the optimal long-term injection frequency. Patients on SR-LAN 30 can be safely and effectively shifted to SR-LAN 60. Copyright 2002 by W.B. Saunders Company.

Product: Somatuline LP 40-60 microspheres

Comment: 20 patients treated with lanreotide PR 60mg microspheres (previously treated by lanreotide PR 30mg), cf abstract 1077

Medipisen identifier: 1277



Address: <http://ipen-london.beaufour-ipen.com/priv/009262.pdf>

Save a Copy Print Email Search Review & Comment Sign

Select Text 118%

For reprint orders, please contact reprints@future-drugs.com Drug Profile

The role of lanreotide Autogel® in the treatment of acromegaly

Marianne Andersen

Acromegaly is a rare disease, but all clinicians have to be aware of the diagnosis in order to minimize the negative consequences of increased levels of growth hormone and IGF-I, and the possible impact of a pituitary macroadenoma. Surgery remains the first-line therapy and may alleviate both hormonal excess and symptoms due to tumor mass effects. Postoperatively, however, many patients may need adjunctive therapy. Somatostatin analogs were marketed for clinical use in the 1980s. The depot formulations of the synthetic somatostatin analogs octreotide and lanreotide, octreotide acetate long-acting repeatable and lanreotide sustained release, were developed by incorporating the analogs into microspheres. The advantage of the new formulation of lanreotide, lanreotide Autogel®, is the prefilled syringe of lanreotide and water. The

CONTENTS
Therapy of acromegaly
Somatostatin analogs

Is a Product Literature Database still needed?

IS view


- Strong investment to maintain PLDs
- Abstract is the standard
- Warrant the exhaustiveness
- Comprehensive tracking is not effective before providers have indexed the papers

End-user view

- Need investment for ad hoc searches
- Full text is needed
- Key papers repository is enough
- Alert set-up from some key publisher's sites

Changing landscape for secondary Abstract & Indexing services

FEDERATED SEARCH EVEN FOR PROFESSIONAL SOURCES




The screenshot displays the QES Qwam E-content Server interface. At the top, the IPSEN logo and navigation menu are visible. The main content area shows a search configuration page with a sidebar on the left containing a tree view of categories like 'Bone tissue' and 'PLGA'. The main panel is titled 'Vos bases sélectionnées / Tout sélectionner / Tout effacer' and lists several selected databases: Embase (Datastar), Medline (Datastar), Medline (Datastar) pour initialisation de corpus, Biosis (Datastar), and Chemical abstracts plus (STN). Below the list, there is a search input field with a placeholder 'Saisir un ou plusieurs critères de recherche dans les champs appropriés' and a search button labeled 'RECHERCHE'. There is also an 'EFFACER' button and a note 'Voir les 20 références les plus récentes, au format Titre'.

- TO COMBINE PROFESSIONAL SOURCES FROM DIFFERENT VENDORS AND GOOGLE SEARCHES

- TO BRIDGE DISPARATE SILOS OF INFORMATION

PLD : Return of investment of our virtual library

Open URL to link to publisher sites and give access to full text



The screenshot displays the QES Qwam E-content Server interface. At the top, the IPSEN logo and navigation menu are visible. The search bar contains 'igf1' and the results are filtered to 'Articles'. The main content area shows a detailed record for a scientific article:


- Titre :** Seasonal and sex-specific mRNA levels of key endocrine genes in adult yellow perch (*Perca flavescens*) from Lake Erie.
- Source :** Marine biotechnology (New York N.Y.), {Mar-Biotechnol}, Mar-Apr 2009 (epub: 23 Sep 2008), vol. 11, no. 2, p. 210-2
- Numéro ISSN :** 1436-2228.
- Domaine :** 0100892712. IP.nlm.
- Auteur(s) :** Lynn-S-G, Powell-K-A, Westneat-D-F, Shepherd-B-S.
- Affiliation de l'auteur :** Department of Biology, University of Kentucky, Lexington, KY 40506-0225, USA, sqlynn@msu.edu.
- Année de publication :** 2009.
- Date de publication :** 20090300.
- Mise à jour :** Date created: 20090223 Date completed: 20090519.
- Notes :** Publication model: Print-Electronic; Cited medium: Print; ISSN: Print.
- Langue :** English.
- Etat du document :** Collecte
- Identifiant QES :** 20090701/1246409590850.xml
- Base :** MEDLINE IPSEN
- Login du collecteur :** Fabienne BERTHET
- Veille de collecte :** Q0086 IGF1 FOR QES
- Date de collecte :** 20090701 02:53:10:608
- Descripteur(s) :** FISH-PROTEINS/*GE (genetics); FRESH-WATER/*; PERCHES/*GE (genetics); *ME (**metabolism**); RNA-MESS... SEASONS/*; AGE-FACTORS; ANIMALS; ESTROGEN-RECEPTOR-ALPHA/GE (genetics); FEMALE; GROWTH-HORMONE/GE (genetic FACTOR-I/GE (genetics); LIVER/ME (**metabolism**); MALE; OVARY/ME (**metabolism**); PITUITARY-GLAND/ME (**metabolism**); I POLYMERASE-CHAIN-REACTION; SEX-FACTORS. RN 0 (Estrogen-Receptor-alpha); 0 (Fish-Proteins); 0 (RNA-Messenger); 6776. 9002-72-6 (Growth-Hormone).
- Résumé :** To better understand the endocrine mechanisms that underlie sexually dimorphic growth (females grow faster) in ye quantitative polymerase chain reaction (qPCR) was used to measure pituitary, liver, and ovary mRNA levels of genes related to species. Adult perch were collected from Lake Erie and body mass, age, gonadosomatic index (I (G)), hepatosomatic index (I (hormone (GH), prolactin, somatolactin, insulin-like growth factor 1b (IGF-1b), estrogen receptor alpha (esr1), estrogen receptor (cyp19a1a) were measured. Females had higher body mass, I (H), and liver esr1 mRNA level than males, while males had high cyp19a1a mRNA levels. In both sexes, season had a significant effect on GH and liver IGF-1b mRNAs with higher levels occurrn with higher liver cyp19a1a mRNA levels. For females, I (G), liver esr1, and ovary cyp19a1a mRNA levels were higher in autumi mRNA levels showed a significant negative correlation with pituitary GH and liver IGF-1b mRNA levels. The most significant (p

Additional options include 'Version imprimable', 'Modifier cet article', and 'Supprimer cet article'. A footer note reads: 'Commander sur support papier une copie du document original des références sélectionnées ci-dessus'.

How federated search enables the “discoverability” of the expensive resources in our library, while protecting the Intellectual Property Rights of content providers

PLD : ASSISTED INDEXATION

- Text mining or semantic tool can be integrated upstream
- Automatic categorization of search results into descriptive folders
- Text mining tools can be integrated downstream as well to analyze the content



The screenshot displays the QES Qwam E-content Server interface. The top navigation bar includes the IPSEN logo, a search bar, and menu items: ACCUEIL, MES RECHERCHES, MES VEILLES, MES PANIERS, MON HISTORIQUE, AIDE, and CONTACT. A user is logged in as 'Deconnexion' with an 'English' language option. The search results page shows a search for 'metabolism' with filters for Articles, Patents, and All. A detailed view of a search result is shown, including the title, edition, source, ISSN, document type, number of references, domain, author(s), author affiliation, volume, and number.

RECHERCHE
metabolism
OK
 Articles
 Patents
 All

CATALOGUE
Plan de classement Ipsen
Thesaurus Ipsen
IGF-1
Growth
Growth
Therapeutic use and clinical trial
Controlled clinical trial
Controlled clinical trial
Randomized clinical trial
Case report
Adverse event/safety
Adverse event/safety
Cell cycle
Metabolism
Metabolism
Therapeutic use and clinical trial

QES Qwam E-content Server Deconnexion
English

ACCUEIL MES RECHERCHES MES VEILLES MES PANIERS MON HISTORIQUE AIDE CONTACT

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. >

Base : Base de connaissance IPSEN

Titre

Titre : ABM/P-15 modulates proliferation and mRNA synthesis of growth factors of periodontal ligament cells. +

Edition : +

Source : Acta odontologica Scandinavica, {Acta-Odontol-Scand}, 2009, vol. 67, no. 2, p. 65-73, +

Numéro ISSN : 1502-3850. +

Type de document : +

Nombre de références : +

Domaine : 0000370344. IP NLM. +

Auteur(s) : Emecen-Pinar, Akman-Abdullah-Cevdet, Hakki-Sema-Sezgin, Hakki-Erdogan-Esref, Demiralp-Burak, Toezuem-Tolga-Fikret, Nohutcu-Rahime-Meral. +

Affiliation de l'auteur : Department of Periodontology, College of Dentistry, Ohio State University, Columbus, +

Volume : +

Numéro : +

CONCLUSIONS – driven by end-user needs and attitudes

- **We still do need traditional tools as a first step**
 - Multiple sources needed to assure exhaustiveness
 - Federated search engines and duplicate remove modules requested
- **However this first step is more and more useful only for information professionals**
 - Human analysis is asked – Brain is the key tool
 - Tools helpful at this step to visualize the analysis
- **Unique platform combining end-user and professional requirements**
- **Such platform needs to integrate different tools**
 - Automatic categorization
 - Electronic document management system
 - Linking to external applications and sources
 - Linking to analysis or visualization tools



THANK YOU

fabienne.berthet@ipsen.com

